Sagimet Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sagimet Biosciences (SGMT).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

2S.Buy

11Buy

1Sell

Consensus RatingBuy# Analysts14Avg. Consensus PT$25Upside to Avg. PT+208.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$29
Oct 2, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$25→$26
Oct 1, 2026	Oppenheimer	Jay Olson	PT Raise	Outperform	$33→$38
Oct 1, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$29→$27
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Sell	$7
Sep 9, 2026	Barclays	Eliana Merle	Upgrade	Equal-Weight→Overweight	$8→$18
Sep 9, 2026	Cantor Fitzgerald	Yanni Souroutzidis	Initiate	Overweight	$11
Aug 25, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$29
Aug 14, 2026	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$12→$29
Aug 12, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$49→$56
May 19, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$35→$12
May 4, 2026	Canaccord Genuity	Edward Nash	PT Raise	Buy	$28→$49
Apr 29, 2026	Guggenheim	Seamus Fernandez	PT Cut	Buy	$27→$25
Mar 11, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$29
Feb 3, 2026	Guggenheim	Seamus Fernandez	Initiate	Buy	$27
Feb 3, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$29
Jan 28, 2026	Barclays	Eliana Merle	Initiate	Equal-Weight	$8
Nov 14, 2025	Citizens	Jonathan Wolleben	PT Raise	Market Outperform	$33→$35
Oct 22, 2025	Clear Street	Kaveri Pohlman	Initiate	Buy	$29
Oct 2, 2025	Canaccord Genuity	Edward Nash	Maintained	Buy	$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

Guggenheim analyst Seamus Fernandez maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $25 to $26.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

Oppenheimer analyst Jay Olson maintains Sagimet Biosciences (NASDAQ:SGMT) with a Outperform and raises the price target from $33 to $38.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $29 to $27.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Sagimet Biosciences (NASDAQ:SGMT) with a Sell and announces $7 price target.

Benzinga Newsdesk

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.

Avi Kapoor

Sagimet Biosciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Sagimet Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

PRO
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

PRO
Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

PRO
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

PRO
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

People Also Watch

People Also Watch

Sagimet Biosciences Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Sagimet Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

PROGuggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

PROOppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

PROCitizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

PROGoldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

PRO
Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26

PRO
Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38

PRO
Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27

PRO
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target